Home Cart Sign in  
Chemical Structure| 909910-43-6 Chemical Structure| 909910-43-6

Structure of A 83-01
CAS No.: 909910-43-6

Chemical Structure| 909910-43-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

A 83-01 (GMP) is a GMP-grade A 83-01. GMP-grade small molecules can be used as ancillary reagents in cell therapy. A 83-01 is an effective ALK4/5/7 inhibitor.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of A 83-01

CAS No. :909910-43-6
Formula : C25H19N5S
M.W : 421.52
SMILES Code : S=C(N1N=C(C2=NC(C)=CC=C2)C(C3=CC=NC4=CC=CC=C34)=C1)NC5=CC=CC=C5
MDL No. :MFCD08705403
InChI Key :HIJMSZGHKQPPJS-UHFFFAOYSA-N
Pubchem ID :16218924

Safety of A 83-01

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of A 83-01

RTK

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
synovial fibroblasts 100 nM overnight To investigate the role of the SMAD2 signaling pathway in TGFβ and LM-111-induced μMP-3 expression by blocking it with A-83-01. Results showed that A-83-01 significantly reduced μMP-3 expression, confirming the importance of the SMAD2 pathway in μMP-3 induction. PMC1856036
human urine-derived cells (hUCs) 0.5 µM 7 days significantly improves the reprograμMing efficiency of hUCs PMC4939659
Human Chemically Induced Liver Progenitor Cells (hCLiPs) 0.5 µM 14-16 days Induce the formation of human chemically induced liver progenitor cells (hCLiPs) and successfully generate hepatobiliary organoids. PMC11346037
Mature hepatocytes 1 μM Changed every day Convert mature hepatocytes to liver progenitor-like cells PMC8039967
Hepatic stellate cells 1 μM 3 days Inhibit the activation of hepatic stellate cells PMC8039967
Mesenchymal stem cells (MSCs) 2 μM To enhance the iμMunomodulatory function of MSCs and improve their iμMunosuppressive effects on T cells and macrophages. PMC9530344
human urine-derived cells 0.5 µM 7 days Enhance the reprograμMing efficiency of hUCs PMC4939659
Mature Hepatocytes (MHs) 1 μM Media changed daily Conversion of mature hepatocytes into liver progenitor-like cells (HepLPCs) PMC8039967
Primary Hepatic Stellate Cells (HSCs) 1 μM 3 days and 7 days Inhibition of HSC activation and proliferation PMC8039967

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Colon 26 cell tumor model Intraperitoneal injection 20 mg/kg Single injection, exposed to hyperoxia for 24 hours To evaluate the effects of A-83-01 on tumor vasculature by observing changes in tumor vascular parameters through DCE-MRI and diffusion-weighted imaging. Results showed that A-83-01 treatment significantly increased IAUGC60, Ktrans, and vp values for both Gd-DTPA and Gd-L, indicating improved tumor vascular function and predicting the delivery of liposomal drugs to the tumor. PMC2788254
C57BL/6J mice CCL4-induced liver fibrosis model Intraperitoneal injection 5 mg/kg Twice a week for a total of 4 times Induce endogenous CD24+ liver progenitor cells and inhibit the activation of hepatic stellate cells, thereby improving liver fibrosis PMC8039967
BALB/c mice Delayed hypersensitivity and acute peritonitis models Tail vein injection 1 mg/kg Single or repeated administration, repeated administration at 0 and 21 hours To evaluate the anti-inflammatory effects of SM-MSCs in vivo, showing that SM-MSCs were more effective than Ctrl-MSCs in inhibiting inflammatory responses. PMC9530344
C57BL/6J mice CCL4-induced liver fibrosis model Intraperitoneal injection 400 μmol/kg Induction of endogenous CD24+ liver progenitor cells and inhibition of HSC activation, leading to improved liver fibrosis PMC8039967

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.37mL

0.47mL

0.24mL

11.86mL

2.37mL

1.19mL

23.72mL

4.74mL

2.37mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories